Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes
2025-522701-38-00Phase 4Authorised
- Sponsor
- Biobizkaia Health Research Institute
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of faricimab in age-related macular degeneration (AMD), sponsored by Biobizkaia Health Research Institute. Primary endpoint: Resolution of subretinal hyperreflective material at week 16. Planned start Feb 2026; status: authorised.
02
Drugs
faricimab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2025-522701-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522701-38-00.